FDA accepts supplemental filing sBLA for Opdivo (nivolumab) dosing every four weeks for all indications.- BMS

Bristol-Myers Squibb Company has announced that the FDA accepted its supplemental Biologics License Applications (sBLAs) to update Opdivo (nivolumab) dosing to include 480 mg infused over 30 minutes every four weeks for all currently approved monotherapy indications. The applications are under review with an action date of 5 March 2018.